We have been reasonably sanguine about the markets because valuations don't look overly expensive. In Europe, earnings have clearly had the global recovery element to them.
We are caught in a hiatus, awaiting an improvement in the economic data from the United States.
Clearly drug companies that have got strong products have done a great job.
